- Home
- Publications
- Publication Search
- Publication Details
Title
How should we treat newly diagnosed multiple myeloma patients?
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2013, Issue 1, Pages 488-495
Publisher
American Society of Hematology
Online
2013-12-06
DOI
10.1182/asheducation-2013.1.488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
- (2013) S. Bringhen et al. HAEMATOLOGICA
- Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
- (2012) M.-V. Mateos et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
- (2012) A. Palumbo et al. HAEMATOLOGICA
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
- (2012) María-Victoria Mateos LEUKEMIA RESEARCH
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
- (2011) P. M. Fayers et al. BLOOD
- Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
- (2011) M.-V. Mateos et al. BLOOD
- Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
- (2011) G. J. Morgan et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03
- (2011) Susanna J. Jacobus et al. BRITISH JOURNAL OF HAEMATOLOGY
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
- (2010) A. Waage et al. BLOOD
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
- (2010) J. A. Zonder et al. BLOOD
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
- (2010) Meral Beksac et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- (2009) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
- (2008) H. Ludwig et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started